基于抗苗勒管激素和体重的个体化FSH给药在高反应潜能患者中的临床结局
该回顾性分析纳入153例基线血清抗苗勒管激素(AMH)高于35 pmol/l的高反应潜能患者,比较个体化固定剂量促卵泡激素δ(基于AMH和体重,n=78)与常规每日起始150 IU促卵泡激素α(n=75)的疗效与安全性。结果显示个体化给药组卵泡数、孕酮升高比例、获卵数更低,卵巢过度刺激综合征(OHSS)风险更低,而持续妊娠率两组相近。
要点
- 个体化促卵泡激素δ组直径≥12 mm卵泡数、获卵数均低于常规促卵泡激素α组,差异有统计学意义。
- 常规促卵泡激素α组OHSS总风险约为个体化组的3倍(16.0% vs 5.1%,P=0.025)。
- 两组新鲜囊胚移植后每启动周期持续妊娠率相近(28.2% vs 24.0%)。
核心结论
- 个体化促卵泡激素δ治疗使高卵巢储备女性的卵巢反应正常化并降低OHSS风险,且不损害妊娠机会,改善了疗效-安全性平衡。
研究设计与样本
- 回顾性分析纳入153例基线血清AMH高于35 pmol/l的高反应潜能患者,个体化固定剂量促卵泡激素δ组78例,常规每日起始150 IU促卵泡激素α组75例。
主要发现
- 刺激结束时直径≥12 mm卵泡数个体化促卵泡激素δ组为12.1±7.0个,常规促卵泡激素α组为18.3±7.0个(P<0.001)。
- 血清孕酮高于3.18 nmol/l的患者比例个体化组为27.3%,常规组为62.7%(P<0.001)。
- 获卵总数个体化组为9.3±6.7个,常规组为17.9±8.7个(P<0.001)。
- 新鲜囊胚移植后每启动周期持续妊娠率个体化组为28.2%,常规组为24.0%。
- 全部病例OHSS风险常规促卵泡激素α组为16.0%,个体化促卵泡激素δ组为5.1%(P=0.025),常规组约为个体化组的3倍;早期中重度OHSS、早期OHSS预防性干预或两者兼有的发生率常规组为26.7%,个体化组为7.7%(P=0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: How does the efficacy and safety of individualized follitropin delta dosing compare with conventional dosing for ovarian stimulation in potential high responders? DESIGN: Retrospective analysis of 153 potential high responders identified on the basis of baseline serum anti-Müllerian hormone (AMH) levels above 35 pmol/l, who were originally randomized to an individualized fixed dose of follitropin delta based on AMH and body weight (n = 78) or to a daily starting dose of 150 IU follitropin alfa (n = 75). RESULTS: At the end of stimulation, patients treated with individualized follitropin delta or conventional follitropin alfa had 12.1 ± 7.0 and 18.3 ± 7.0 (P < 0.001) follicles measuring 12 mm or wider, and 27.3% and 62.7% had serum progesterone levels higher than 3.18 nmol/l (P < 0.001), respectively. Overall number of oocytes in these two respective arms was 9.3 ± 6.7 and 17.9 ± 8.7 (P < 0.001), and the ongoing pregnancy rate per started cycle after fresh blastocyst transfer was 28.2% and 24.0%. The risk of ovarian hyperstimulation syndrome (OHSS) for all cases was three times higher in the conventional follitropin alfa arm at 16.0% versus 5.1% with individualized follitropin delta treatment (P = 0.025) and 26.7% versus 7.7% (P = 0.001) for early moderate or severe OHSS, preventive interventions for early OHSS, or both. CONCLUSIONS: Treatment with individualized follitropin delta provides an improved efficacy-safety balance in women with high ovarian reserve, as it normalizes the ovarian response and decreases the risk of OHSS without compromising the chance of pregnancy.
引用
- Višnová H, Papaleo E, Martin FS, et al. Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Müllerian hormone and body weight. Reprod Biomed Online. 2021. PMID: 34756645. doi:10.1016/j.rbmo.2021.08.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。